Did you know that Amazon.com (NASDAQ: AMZN ) has officially unveiled 14 pilot episodes for original series? There doesn't seem to be nearly as much interest as the e-tailer would like, which isn't good news for Amazon stock.
Founder Jeff Bezos has made big investments trying to turn Amazon Instant Video into a legitimate Netflix (NASDAQ: NFLX ) alternative. While it may be the best option at this point, it's worth noting that, of the pilots, an offshoot of the movie Zombieland appears to be most watched, with some 4,700 reviews. Alpha House, starring John Goodman, ranks next at just under 2,100 reviews, and it declines sharply from there, says Tim Beyers of Motley Fool Rule Breakers and Motley Fool Supernova in the following interview with the Fool's Erin Miller.
By contrast, Netflix's most recent original program -- the horror series Hemlock Grove -- rates four out of five stars from more than 270,000 reviewers as of this writing. More than 890,000 have rated House of Cards. Amazon stock is a good buy because of its leadership positions in e-commerce and Internet infrastructure delivered as a service. Instant Video isn't a factor, nor is it a serious threat -- yet -- to Netflix's long-term profit plan, Tim says.
Hot Managed Healthcare Companies To Invest In Right Now: Cancer Genetics Inc (CGIX)
Cancer Genetics, Inc. (CGI), incorporated on April 8, 1999, is an early-stage, diagnostic company. The Company focuses on developing and commercializing genomic tests and services to improve the diagnosis, prognosis and response to treatment (theranosis) of cancer. These cancers include hematological, urogenital and human papillomavirus (HPV)-associated cancers. It provides its tests and services to oncologists and pathologists at hospitals, cancer centers, and physician offices. In January 2012, the Company received CLIA approval for MatBA-SLL, its microarray for risk stratification in small lymphocytic lymphoma (SLL). In February 2013, the Company received CLIA approval for MatBA-DLBCL, its microarray for diagnosis, prognosis and patient monitoring in diffuse large B cell lymphoma (DLBCL). In addition, the Company is developing a series of other genomic tests in its core oncology markets. The Company develops and produces two types of deoxyribonucleic acid (DNA)-based genomic tests: microarrays and probes.
The Company is in the final stages of validating MatBATM-SLL for risk stratification in small lymphocytic lymphoma (SLL), a subset of CLL that presents as a mass, with Memorial Sloan-Kettering Cancer Center and Long Island Jewish / North Shore Hospital. The Company is also internally clinically validating the MatBATM microarray in a variety of additional lymphoma subtypes, including mantle-cell lymphoma (MCL), follicular lymphoma (FL), and diffuses large B cell lymphoma (DLBCL). Its MatBATM array has been designed to measure genetic markers at 80 specific genomic sites where genetic alterations are associated with mature B cell neoplasms.
CGI is also developing microarray tests for the diagnosis, prognosis and theranosis of a range of urogenital cancers. These include the UroGenRA microarray for kidney, prostate and bladder cancers and the UGenRA microarray for endometrial (lining of the uterus), ovarian and cervical cancers. UroGenRA detects genomic changes in over 100 r! egions of the human genome with potential diagnostic and/or prognostic value in one or more of these types of cancer. It has initiated clinical validation for UroGenRA targeting kidney and prostate cancers in collaboration with Memorial Sloan-Kettering Cancer Center. Its UGenRA microarray has been designed as a platform to detect genomic changes occurring in 83 regions of the human genome that have been linked to endometrial, ovarian and cervical cancers In addition, it develop and manufacture a portfolio of fluorescence in situ hybridization (FISH) based DNA probes focused on blood-based and solid cancers that it sell outside the United States. The Company laboratory services include: Oncology Testing Services, which are based on its microarray tests and are available only in its clinical laboratory; Esoteric Oncology Testing Services, which it offers a suite of esoteric oncology testing services for hematological, urogenital and HPV-associated cancers, and Clinical Trial Services, which also utilize its clinical laboratory to provide clinical trial services to biopharmaceutical companies and clinical research organizations.
Hematological Cancer Arrays: MatBA-CLL/SLL, Other Mat-BA and LeukA
MatBA is an oligonucleotide-based microarray the Company developed for the analysis of genomic alterations in mature B-cell neoplasms to determine prognosis and theranosis. MatBA incorporates a common architecture of specific genomic regions that can be applied across the seven major mature B-cell neoplasms. As a group, hematologic cancers (cancers of the blood, bone marrow or lymph nodes) display clinical, pathologic and genetic complexity. Importantly, the clinical course of the six main subtypes of these neoplasms ranges from indolent (follicular lymphoma) to aggressive (diffuse large B-cell lymphoma, mantle cell lymphoma and multiple myeloma), or mixed (chronic lymphocytic leukemia/small lymphocytic lymphoma, or CLL/SLL).
MatBA is designed to detect genomic copy number chan! ges in ma! ture B-cell neoplasms. The test relies on the comparative genomic hybridization of fluorescently differentially-labeled normal DNA and DNA extracted from the cancer specimen (array-CGH). Array-CGH utilizes minimal biopsy material and uses DNA as the analyte (the component whose properties are being measured). MatBA was custom-designed to represent 80 regions of the human genome which have diagnostic and/or prognostic value in one or more of the mature B-cell neoplasm subtypes as identified through our research and analysis efforts. Unlike other technologies such as FISH, array-CGH using MatBA simultaneously permits the detection of genomic gains and losses at multiple locations on a chromosome (loci) that characterize the mature B-cell neoplasm subtypes. For each subtype of B-cell neoplasm, cohorts of specimens with full clinical annotation are evaluated using MatBA to identify associations between single and weighted combinations of genomic gains/losses and clinically relevant endpoints.
The Company offers the application of MatBA for prognostication in one subtype of mature B-cell neoplasm, CLL, where about half of patients experience indolent disease, or slow progression, and the remaining half, a relatively aggressive progression. MatBA-CLL provides genetic-based information to guide clinical management of this disease. In January 2012, MatBA-SLL was approved under CLIA and accordingly may now be offered as an LDT by its laboratory. In January 2013, this assay received approval by CLIA and New-York State for clinical use, and accordingly may now be offered as an LDT by our reference laboratory.
During the year ended December 31, 2012, the Company had similar development of MatBA as a prognostic tool in two of the other main subtypes of mature B-cell lymphomas, namely DLBCL and FL. FL is characterized by a slow progression that in up to approximately 60% of cases transforms to DLBCL, an aggressive lymphoma. Prognostic and theranostic biomarkers of therapeutic options are req! uired for! these diseases.
Urogenital cancer arrays: UroGenRA, UGenRA
The UroGenRA microarray provides diagnostic and prognostic analysis for kidney, bladder and prostate cancer. Its initial launch, UroGenRA-Kidney targets kidney cancer. It also develops extensions of UroGenRA for bladder and prostate cancers. UGenRA provide diagnostic, prognostic and theranostic information for the primary gynecological cancers, cervical, ovarian and endometrial. UroGenRA is a CGH-based array which serves as a platform for the diagnosis, prognosis and theranosis of kidney, prostate and bladder cancers. It represents 101 regions of the human genome potentially with diagnostic, prognostic and/or theranostic value in one or more of these types of cancers. UroGenRA-Kidney For kidney cancer, UroGenRA is specifically designed to classify renal tumors into the four main subtypes (clear cell, papillary, chromophobe and oncocytoma), which is critical to patient management and treatment protocols.
UroGenRA-Prostate for prostate cancer, UroGenRA use prostate core/needle biopsy to assess genomic variability of the cancer and help in the identification of biomarkers for assessment of the risk of recurrence, to assess treatment options for intermediate risk patients, and to explore the genomic aberrations of circulating tumor cells. UroGenRA-Prostate is in the commercial development stage. UroGenRA-Bladder is a diagnosed bladder cancers are defined by the fact or extent of invasion of the muscle. UroGenRA-Bladder is in the clinical development stage.
UGenRA for Endometrial, Ovarian and Cervical Cancers
UGenRA is designed as a platform to detect gains and losses of genomic material in 83 regions of the chromosome associated with responses to particular therapies in patients with endometrial, ovarian and cervical. UGenRA-Endometrial Endometrial cancer is common cancer in women in the United States. In this disease, endometrial hyperplasia is a precursor lesion of endometr! ioid endo! metrial carcinoma (EEC). UGenRA Endometrial is in the clinical development stage.
UGenRA-Ovarian is cases of ovarian cancer. UGenRA Ovarian is in the clinical development stage. As of December 31, 2012, UGenRA-Cervical was approximately 11,270 cases of cervical cancer diagnosed and approximately 4,290 deaths from cervical cancer in the United States. UGenRA Cervical is in the clinical development stage.
Advisors' Opinion:- [By RedChip]
Cancer Genetics, Inc. (NASDAQ: CGIX) had a big run in September; at one point, shares were up more than 130% over their IPO and secondary offering price of $10.
- [By John Udovich]
Biotech and the cancer treatment segment of the biotech market has been a hot area for some time with important cancer stocks like large cap Celgene Corporation (NASDAQ: CELG) and small caps�Array BioPharma (NASDAQ: ARRY), Cancer Genetics Inc (NASDAQ: CGIX), EXACT Sciences Corporation (NASDAQ: EXAS) and�MetaStat Inc (OTCMKTS: MTST) all producing a steady flow of important news�for investors this week or in recent weeks. Consider the following:
- [By Lauren Pollock]
Biopharmaceutical development company CytRx Corp.(CYTR) and early-stage diagnostics company Cancer Genetics Inc.(CGIX) separately disclosed plans to sell stock. CytRx, whose offering of 10 million shares priced at an 18% discount, is aiming to raise money to fund its clinical trials, while Cancer Genetics wants to hire more sales and marketing personnel, as well as fund research and development. CytRx dropped, while Cancer Genetics fell.
Hot Managed Healthcare Companies To Invest In Right Now: Creston PLC (CRE)
Creston Plc is a United Kingdom-based company engaged in insight and communications services. The Company operates in three divisions: Communications division, which offers clients an integrated approach to their marketing and communication strategy, offering a range of services, which include advertising, brand strategy, channel marketing, customer relationship marketing, digital marketing, direct marketing, local marketing, social media marketing and public relations; Health division, which provides an integrated communications solution to the healthcare and pharmaceutical sector and offers services, which include advertising, advocacy, digital and direct marketing, public relations, issues and reputation management and medical education; Insight division, which performs a range of market research services on behalf of its clients, through both qualitative and quantitative means, using face-to-face, telephone and online data collection techniques. Advisors' Opinion:- [By Investment Biker]
Over the years, WAL has changed its loan origination strategy. Post crisis, WAL's i) loan growth has been driven by commercial real estate (CRE) and Commercial & Industrial loans (C&I), ii) Construction and development share of loans has reduced from 24% in 2005 to 7% in 1Q'2013 and iii) completely cessation of new loan origination in the residential mortgage segment.
Best Heal Care Stocks To Invest In Right Now: Retail Properties of America Inc (RPAI)
Retail Properties of America, Inc., formerly Inland Western Retail Real Estate Trust, Inc., incorporated on March 5, 2003, is a fully integrated, self administered and self-managed real estate company that owns and operates shopping centers. The Company is an owner and operator of shopping centers in the United States. As of December 31, 2011, its retail operating portfolio consisted of 259 properties with approximately 3.6 million square feet of gross leasable area (GLA), was diversified across 35 states and includes power centers, community centers, neighborhood centers and lifestyle centers, as well as single-user retail properties. The Company�� retail properties are located in retail districts. In August 2012, the Company sold a 1.04-million-square-foot Cost Plus Distribution Center in Stockton. In September 2012, it disposed 13 former Mervyns locations. In October 2012, it sold 18 non-core and non-strategic assets.
The Company�� shopping centers are anchored or shadow anchored by a grocer, discount department store, wholesale club or retailer that sells basic household goods or clothing. national and regional grocers, discount retailers and other retailers that provide household goods or clothing, including Target, TJX Companies, PetSmart, Best Buy, Bed Bath and Beyond, Home Depot, Kohl��, Wal-Mart, Publix and Lowe��. As of December 31, 2011, over 90% of its shopping centers, based on GLA, were anchored or shadow anchored by a grocer, discount department store, wholesale club or retailers that sell basic household goods or clothing. As of December 31, 2011, it had a retail tenant base that includes approximately 1,500.
Advisors' Opinion:- [By Eric Volkman]
Retail Properties of America (NYSE: RPAI ) isn't keeping all of its rent money for itself. The company has declared a new set of quarterly dividend payments for its shareholders. Holders of all classes of the REIT's common stock will receive $0.165625 per share on July 10 if they're in possession of those shares as of June 28. The firm will also dispense $0.4375 per share of its 7.00% series A cumulative redeemable preferred stock on July 1 to shareholders of record as of June 20.
- [By Ant贸nio Costa]
Retail Properties of America Inc (NYSE: RPAI) has been in an impressive rebound since the lows of August and the stock price action continues to become Bullish. However, RPAI has run into the downtrend line resistance again and this could lead to a brief period of sideways consolidation or price correction from current levels. On watch.
Hot Managed Healthcare Companies To Invest In Right Now: OceanFirst Financial Corp.(OCFC)
OceanFirst Financial Corp. operates as the holding company for OceanFirst Bank that provides community banking services to retail, government, and business customers primarily in Ocean, Monmouth, and Middlesex counties in New Jersey. Its deposit products include money market accounts, savings accounts, interest-bearing checking accounts, non-interest bearing accounts, and time deposits. The company?s loan portfolio comprises conventional first mortgage loans secured by one-to-four family residences, residential mortgage loans, commercial real estate loans, multi-family and land loans, and real estate construction loans; consumer loans, such as home equity loans and lines of credit; and commercial loans. In addition, it offers trust and asset management, and merchant check card services; and sells alternative investment products, including mutual funds, annuities, and life insurance. The company operates 22 branches, as well as a loan production office and a trust and weal th management office. OceanFirst Financial Corp. was founded in 1902 and is based in Toms River, New Jersey.
Advisors' Opinion:- [By Garrett Cook]
In trading on Wednesday, financial shares were relative laggards, down on the day by about 0.24 percent. Top losers in the sector included IRSA Investments and Representations (NYSE: IRS), down 3.2 percent, and OceanFirst Financial (NASDAQ: OCFC), off 2.5 percent.
Hot Managed Healthcare Companies To Invest In Right Now: OpenTable Inc.(OPEN)
OpenTable, Inc. provides restaurant reservation solutions in the United States, Canada, Germany, Japan, Mexico, and the United Kingdom. It offers solutions that form an online network connecting reservation-taking restaurants and people who dine at those restaurants. The company provides electronic reservation book (ERB) that combines proprietary software and computer hardware to deliver a solution, whcih computerizes restaurant host-stand operations. The ERB streamlines and enhances various functions and processes for restaurants, including reservation management, table management, guest recognition, and email marketing. The company also operates opentable.com, a restaurant reservation Website that enables diners to find, choose, and book tables at restaurants on the OpenTable network in real time. In addition, it offers Connect, a Web-based service that enables restaurants to accept online reservations from the OpenTable network, as well as through its mobile application s and restaurants' Websites. Further, the company provides POP program, which lets restaurants offer diners bonus Dining Reward Points for reservations at select times; and telephone reservation management services for restaurants. Additionally, it operates toptable.com, a restaurant reservation site; designs, builds, and operates the OTRestaurant Website, which serves as an information and services portal for its restaurant customers; and offers versions of the OpenTable Websites for use on mobile devices, as well as free mobile applications. OpenTable, Inc. was founded in 1998 and is headquartered in San Francisco, California.
Advisors' Opinion:- [By John Udovich]
Online review sites have become the first place many consumers turn to before making any type of purchase with online review stocks like Angie's List Inc (NASDAQ: ANGI), OpenTable Inc (NASDAQ: OPEN), Yelp Inc (NYSE: YELP) and Tripadvisor Inc (NASDAQ: TRIP) being some of the publicly traded options for investors. But what is the best performing online review stock? First, here are the options to choose from:
- [By Lee Jackson]
OpenTable Inc. (NASDAQ: OPEN) was downgraded to Equal Weight from Overweight on valuation by Morgan Stanley.
Starbucks Corp. (NASDAQ: SBUX) was started as Outperform with an $80 price target (versus $72.14 close) at Wedbush.
- [By Garrett Cook]
In trading on Friday, technology shares were relative leaders, up on the day by about 0.63 percent. Meanwhile, top gainers in the sector included OpenTable (NASDAQ: OPEN), up 47 percent, and China Digital TV Holding Co (NYSE: STV), up 9 percent.
Hot Managed Healthcare Companies To Invest In Right Now: Blucora Inc (BCOR)
Blucora, Inc., formerly InfoSpace, Inc., is a provider of online solutions for consumers and business partners. The Company owns and operates two Internet businesses. Through its InfoSpace business, the Company provides online search and monetization solutions to a network of more than 100 global partners. Through TaxACT, The Company provides online tax preparation solutions to consumers and professional preparers. The Company's search business consists primarily of a business to business offering that provides its search technology, aggregated content and services to its distribution partners. The search business also offers search services directly to consumers through its own Internet search properties. On June 22, 2011, InfoSpace sold its Mercantila e-commerce business to Zoo Stores, Inc. On January 31, 2012, InfoSpace acquired TaxACT Holdings, Inc. and its subsidiary, 2nd Story Software, Inc. In August 2013, the Company announced that it has completed the acquisition of Monoprice.
InfoSpace primarily offers search services through the Web properties of its distribution partners, which are generally private-labeled and customized to address the requirements of each distribution partner. The search business also distributes aggregated search content through its own Websites, such as Dogpile.com and WebCrawler.com. The Search segment consists of the Company�� search services operations and the Tax Preparation segment is the TaxACT business. The Company�� revenues are generated primarily from its Web search services. The Company�� metasearch technology offers users a search experience, which combines the results of several search engine content providers, including Google, Yahoo!, and Bing, among others, and aggregates, filters, and prioritizes the results. This combination provides a more relevant search results page and leverages the investments made by its Search Customers to continually improve the user experience. Partner versions of its Web offerings are private-labeled and d! elivered with each distribution partner�� requirements.
The Tax Preparation segment generates its revenue through three primary methods: the sale of state and upgraded federal income tax preparation software and online services to consumers, the sale of ancillary services to any user, paid or not, and the sale of its professional edition income tax preparation software to professional tax preparers. The ancillary services include, among other things, additional support, data archiving, a deferred payment option, and a bank card product.
Advisors' Opinion:- [By Canadian Value]
Position % of Fund Assets 1) First American Financial Corp. (FAF) 7.0% 2) Apple, Inc. (AAPL) 6.5% 3) Coinstar, Inc. (CSTR) 4.8% 4) EMC Corp. (EMC) 4.4% 5) Coach, Inc. (COH) 4.4% 6) Kohl's Corp. (KSS) 4.1% 7) Blucora, Inc. (BCOR) 4.0% 8) Tetra Tech, Inc. (TTEK) 3.1% 9) OM Group, Inc. (OMG) 3.0% 10) American International Group, Inc. (AIG) 2.8% TOTAL 44.1% One area that we believe still offers some value in the market is in high quality, large��ap technology stocks that may be momentarily out��f��avor as they transition from rapid growth to slower growth. In particular, we become interested when that transition is also accompanied by a change in capital allocation policies designed to return more cash to shareholders in the form of dividends and share repurchases. We believe that Apple and EMC are two of the absolute highest quality technology businesses in the world and both have recently announced very material, shareholder��friendly changes to how they will allocate capital.
- [By Igor Novgorodtsev]
Combining Perion's and Conduit's number allows us to compare a "new Perion" to its peer group: AVG, IACI, AOL (AOL), and Blucora (BCOR). The numbers are nothing short of incredible demonstrating how grossly the new company is underpriced.
- [By Michael Lewis]
Sea change
As with many industries, tax prep is witnessing a period of technological disruption in the form of Web-based software. Intuit (NASDAQ: INTU ) is the leader in the space with its Turbo Tax product. Lesser-known Blucora (NASDAQ: BCOR ) has its hand in the game as well with TaxACT. The latter is a small but healthy business. TaxACT maintains strong margins and grows at roughly 8% to 10% annually. Currently, the company maintains around 12% of online tax-prep market share.
No comments:
Post a Comment